<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Chemical drug &#8211; Accestra Consulting</title>
	<atom:link href="https://www.accestra.com/tag/chemical-drug/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.accestra.com</link>
	<description>Your long term strategic partner for regulatory compliance.</description>
	<lastBuildDate>Wed, 10 Jul 2019 10:38:46 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.5.5</generator>

<image>
	<url>https://www.accestra.com/wp-content/uploads/2019/03/cropped-accestra2-32x32.png</url>
	<title>Chemical drug &#8211; Accestra Consulting</title>
	<link>https://www.accestra.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>2018 Drug Review and Approval Report of China CDE (Part I-Chemical Drug)</title>
		<link>https://www.accestra.com/2018-drug-review-and-approval-report-of-china-cde-part-i-chemical-drug/</link>
		
		<dc:creator><![CDATA[mona.zhang]]></dc:creator>
		<pubDate>Wed, 10 Jul 2019 10:27:04 +0000</pubDate>
				<category><![CDATA[Pharmaceutical]]></category>
		<category><![CDATA[CDE 2018 report]]></category>
		<category><![CDATA[Chemical drug]]></category>
		<category><![CDATA[China CDE]]></category>
		<category><![CDATA[IND]]></category>
		<category><![CDATA[NDA]]></category>
		<category><![CDATA[Review and approval]]></category>
		<guid isPermaLink="false">http://www.accestra.com/?p=2484</guid>

					<description><![CDATA[On 2nd July, 2019, China CDE-NMPA published the 2018 working Report, summarizing the drug review and approval statistic data in the past year. See below for the details. 1- Overall Statistic It can be seen from Figure 1, 2, 3 and 4, the backlog of drug applications in CDE has been greatly alleviated: the application&#8230;]]></description>
										<content:encoded><![CDATA[
<p>On 2<sup>nd</sup> July, 2019, China CDE-NMPA
published the 2018 working Report, summarizing the drug review and approval
statistic data in the past year.</p>



<p>See below for the details.</p>



<p><strong>1- Overall Statistic</strong></p>



<p> It can be seen from Figure 1, 2, 3 and 4, the backlog of drug applications in CDE has been greatly alleviated: the application number waiting in line has dropped from nearly 22,000 at the peak of year 2015 to 3,440 in year 2018; the review completion rate for all types of drug applications in 2018 has exceeded 90%. </p>



<div class="wp-block-image"><figure class="aligncenter is-resized"><img fetchpriority="high" decoding="async" src="https://www.accestra.com/wp-content/uploads/2019/07/1-2-1024x595.png" alt="" class="wp-image-2485" width="595" height="345" srcset="https://www.accestra.com/wp-content/uploads/2019/07/1-2-1024x595.png 1024w, https://www.accestra.com/wp-content/uploads/2019/07/1-2-300x174.png 300w, https://www.accestra.com/wp-content/uploads/2019/07/1-2-768x446.png 768w, https://www.accestra.com/wp-content/uploads/2019/07/1-2-600x349.png 600w, https://www.accestra.com/wp-content/uploads/2019/07/1-2.png 1045w" sizes="(max-width: 595px) 100vw, 595px" /><figcaption>Figure 1. Drug application total number from 2015 to 2018 </figcaption></figure></div>



<div class="wp-block-image"><figure class="aligncenter is-resized"><img decoding="async" src="https://www.accestra.com/wp-content/uploads/2019/07/2-1-1024x604.png" alt="" class="wp-image-2486" width="603" height="356" srcset="https://www.accestra.com/wp-content/uploads/2019/07/2-1-1024x604.png 1024w, https://www.accestra.com/wp-content/uploads/2019/07/2-1-300x177.png 300w, https://www.accestra.com/wp-content/uploads/2019/07/2-1-768x453.png 768w, https://www.accestra.com/wp-content/uploads/2019/07/2-1-600x354.png 600w, https://www.accestra.com/wp-content/uploads/2019/07/2-1.png 1092w" sizes="(max-width: 603px) 100vw, 603px" /><figcaption>  Figure 2. Total number of completed drug review by CDE from 2015 to 2018 <br> (By different drug category) </figcaption></figure></div>



<div class="wp-block-image"><figure class="aligncenter is-resized"><img decoding="async" src="https://www.accestra.com/wp-content/uploads/2019/07/3-1-1024x602.png" alt="" class="wp-image-2487" width="608" height="357" srcset="https://www.accestra.com/wp-content/uploads/2019/07/3-1-1024x602.png 1024w, https://www.accestra.com/wp-content/uploads/2019/07/3-1-300x176.png 300w, https://www.accestra.com/wp-content/uploads/2019/07/3-1-768x452.png 768w, https://www.accestra.com/wp-content/uploads/2019/07/3-1-600x353.png 600w, https://www.accestra.com/wp-content/uploads/2019/07/3-1.png 1093w" sizes="(max-width: 608px) 100vw, 608px" /><figcaption> Figure 3. Total number of completed drug review by CDE from 2015 to 2018 <br> (By different application type) </figcaption></figure></div>



<div class="wp-block-image"><figure class="aligncenter is-resized"><img loading="lazy" decoding="async" src="https://www.accestra.com/wp-content/uploads/2019/07/4-1.png" alt="" class="wp-image-2488" width="639" height="314" srcset="https://www.accestra.com/wp-content/uploads/2019/07/4-1.png 850w, https://www.accestra.com/wp-content/uploads/2019/07/4-1-300x147.png 300w, https://www.accestra.com/wp-content/uploads/2019/07/4-1-768x377.png 768w, https://www.accestra.com/wp-content/uploads/2019/07/4-1-600x294.png 600w" sizes="(max-width: 639px) 100vw, 639px" /><figcaption>  Figure 4. The drug application number waiting in line for CDE review <br> <br></figcaption></figure></div>



<p><strong>2-  Statistic of Chemical Drugs -Overall</strong></p>



<div class="wp-block-image"><figure class="aligncenter is-resized"><img loading="lazy" decoding="async" src="https://www.accestra.com/wp-content/uploads/2019/07/5-1-1024x605.png" alt="" class="wp-image-2489" width="567" height="335" srcset="https://www.accestra.com/wp-content/uploads/2019/07/5-1-1024x605.png 1024w, https://www.accestra.com/wp-content/uploads/2019/07/5-1-300x177.png 300w, https://www.accestra.com/wp-content/uploads/2019/07/5-1-768x453.png 768w, https://www.accestra.com/wp-content/uploads/2019/07/5-1-600x354.png 600w, https://www.accestra.com/wp-content/uploads/2019/07/5-1.png 1094w" sizes="(max-width: 567px) 100vw, 567px" /><figcaption> Figure 5. Chemical drug application statistics from 2015 to 2018 </figcaption></figure></div>



<div class="wp-block-image"><figure class="aligncenter is-resized"><img loading="lazy" decoding="async" src="https://www.accestra.com/wp-content/uploads/2019/07/6.png" alt="" class="wp-image-2491" width="582" height="346" srcset="https://www.accestra.com/wp-content/uploads/2019/07/6.png 927w, https://www.accestra.com/wp-content/uploads/2019/07/6-300x178.png 300w, https://www.accestra.com/wp-content/uploads/2019/07/6-768x456.png 768w, https://www.accestra.com/wp-content/uploads/2019/07/6-600x357.png 600w" sizes="(max-width: 582px) 100vw, 582px" /><figcaption> Figure 6. Number of completed chemical drug review by CDE in 2018 </figcaption></figure></div>



<div class="wp-block-image"><figure class="aligncenter is-resized"><img loading="lazy" decoding="async" src="https://www.accestra.com/wp-content/uploads/2019/07/表1-1024x332.png" alt="" class="wp-image-2500" width="777" height="252" srcset="https://www.accestra.com/wp-content/uploads/2019/07/表1-1024x332.png 1024w, https://www.accestra.com/wp-content/uploads/2019/07/表1-300x97.png 300w, https://www.accestra.com/wp-content/uploads/2019/07/表1-768x249.png 768w, https://www.accestra.com/wp-content/uploads/2019/07/表1-600x194.png 600w, https://www.accestra.com/wp-content/uploads/2019/07/表1.png 1503w" sizes="(max-width: 777px) 100vw, 777px" /><figcaption> Table 1 Detailed information of completed chemical drug review by CDE in 2018 <br> <br> *Note: &#8220;other&#8221; refers: 1) the applicant withdrawal the application, 2) Supplementary information is required from applicant after the review, 3) the application directly submitted to Drug Registration Management Bureau of NMPA instead of CDE, 4) the combination application of medical device, 5) API/excipient/package material application for linked review procedure. </figcaption></figure></div>



<p> <strong>3-  Statistic of Chemical Drugs -IND</strong></p>



<div class="wp-block-image"><figure class="aligncenter is-resized"><img loading="lazy" decoding="async" src="https://www.accestra.com/wp-content/uploads/2019/07/7.png" alt="" class="wp-image-2493" width="585" height="543" srcset="https://www.accestra.com/wp-content/uploads/2019/07/7.png 761w, https://www.accestra.com/wp-content/uploads/2019/07/7-300x279.png 300w, https://www.accestra.com/wp-content/uploads/2019/07/7-600x557.png 600w" sizes="(max-width: 585px) 100vw, 585px" /></figure></div>



<div class="wp-block-image"><figure class="aligncenter is-resized"><img loading="lazy" decoding="async" src="https://www.accestra.com/wp-content/uploads/2019/07/7-2.png" alt="" class="wp-image-2494" width="590" height="633" srcset="https://www.accestra.com/wp-content/uploads/2019/07/7-2.png 673w, https://www.accestra.com/wp-content/uploads/2019/07/7-2-280x300.png 280w, https://www.accestra.com/wp-content/uploads/2019/07/7-2-600x644.png 600w" sizes="(max-width: 590px) 100vw, 590px" /><figcaption> Figure 7. Therapeutic areas distribution of chemical drugs IND applications in 2018 </figcaption></figure></div>



<div class="wp-block-image"><figure class="aligncenter is-resized"><img loading="lazy" decoding="async" src="https://www.accestra.com/wp-content/uploads/2019/07/8.png" alt="" class="wp-image-2496" width="605" height="552" srcset="https://www.accestra.com/wp-content/uploads/2019/07/8.png 848w, https://www.accestra.com/wp-content/uploads/2019/07/8-300x274.png 300w, https://www.accestra.com/wp-content/uploads/2019/07/8-768x701.png 768w, https://www.accestra.com/wp-content/uploads/2019/07/8-600x548.png 600w" sizes="(max-width: 605px) 100vw, 605px" /><figcaption>Figure 8. Indication distribution of innovative chemical drugs IND approved in 2018 </figcaption></figure></div>



<p><strong>4-  Statistic of Chemical Drugs -NDA</strong></p>



<div class="wp-block-image"><figure class="aligncenter is-resized"><img loading="lazy" decoding="async" src="https://www.accestra.com/wp-content/uploads/2019/07/9.png" alt="" class="wp-image-2498" width="625" height="367" srcset="https://www.accestra.com/wp-content/uploads/2019/07/9.png 847w, https://www.accestra.com/wp-content/uploads/2019/07/9-300x176.png 300w, https://www.accestra.com/wp-content/uploads/2019/07/9-768x451.png 768w, https://www.accestra.com/wp-content/uploads/2019/07/9-600x352.png 600w" sizes="(max-width: 625px) 100vw, 625px" /><figcaption> Figure 9. Chemical drug NDA applications from 2015 to 2018 </figcaption></figure></div>



<div class="wp-block-image"><figure class="aligncenter is-resized"><img loading="lazy" decoding="async" src="https://www.accestra.com/wp-content/uploads/2019/07/10.png" alt="" class="wp-image-2503" width="615" height="281" srcset="https://www.accestra.com/wp-content/uploads/2019/07/10.png 697w, https://www.accestra.com/wp-content/uploads/2019/07/10-300x137.png 300w, https://www.accestra.com/wp-content/uploads/2019/07/10-600x275.png 600w" sizes="(max-width: 615px) 100vw, 615px" /><figcaption>Figure 10. Approved NDA number from 2015 to 2018 (chemical drugs)</figcaption></figure></div>



<p> </p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
